Analyst consensus rating
Atara Biotherapeutics Analyst Rating: Strong Buy
ATRA is rated Strong Buy by 3 analysts with a $13.67 target. As of 2026-08-23.
Direct answer
Atara Biotherapeutics's consensus rating is Strong Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $13.67.
Forecast evidence checked August 23, 2026.
Get free Atara Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $9.70
- Average price target
- $13.67
- High price target
- $18.00
- Low price target
- $10.00
- Low target gap
- +3.1%
- Target upside
- +40.9%
- High target gap
- +85.6%
- Target range width
- 82.5%
- Consensus rating
- Strong Buy
- Analysts
- 3
- Evidence date
- August 23, 2026
- Valid through
- August 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Atara Biotherapeutics?
Atara Biotherapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $13.67.
How far are Atara Biotherapeutics's low and high targets from the recorded price?
The low target implies +3.1%, while the high target implies +85.6%.
How many analysts are included in Atara Biotherapeutics's consensus?
The verified consensus includes 3 analysts.
How is Atara Biotherapeutics's target upside or downside calculated?
The average target of $13.67 is divided by the recorded price of $9.70, then one is subtracted to produce +40.9%. This does not guarantee a future return.
When was Atara Biotherapeutics's analyst forecast verified?
The data was verified on 2026-08-23. The dataset is valid through 2026-08-30.